Accelovance, a global CRO focusing in vaccines, oncology, and general medicine, has announced further expansion of European CRO services with the acquisition of THERAMetrics Holding's three CRO subsidiaries and phase I unit in Germany, Italy and Romania. In addition to the employees and facilities associated with these European subsidiaries, Accelovance will also assume management of THERAMetrics' ongoing clinical program work in the U.S.

Stephen J. Trevisan, CEO of Accelovance, said, "Accelovance is excited to continue its European expansion into Germany, Italy and Romania and to welcome the addition of these talented employees to the Accelovance family. We appreciate the important opportunity to continue working on the valuable assets of THERAMetrics' current sponsors, and look forward to supporting their needs in successfully delivering on their programs."

The acquisition adds to Accelovance's European and service expansion efforts over the last two years with the acquisition and integration of service providers Altair Clinical and Clinquest.

THERAMetrics is a global technology-based contract R&D organization dedicated to providing a full range of technological solutions through the entire value chain of drug discovery and development. The company is headquartered in Stans, Switzerland.